Trimetazidine, an anti-ischemic (anti-anginal) metabolic agent, could improve myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity and results in a reduction in fatty acid oxidation and a stimulation of glucose
Trimetazidine-N-oxide, the major active metabolite of Trimetazidine, is a selective long-chain inhibitor of 3-ketoyl coenzyme A thiolase (IC50: 75 nM) with anti-oxidant, anti-inflammatory, antinociceptive, and gastroprotective properties.